Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare HoldingsJSE:APN +0.10%72 Return-on-Tangible-Equity is 12.75% as of Dec. 2025, which is 60% below its 10-year median of 31.89. GuruFocus rates JSE:APN with a GF Score™ of 72/100 and a GF Value™ of R170.84 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 900 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 81.22% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Aspen Pharmacare Holdings's annualized net income for the quarter that ended in Dec. 2025 was R2,944 Mil. Aspen Pharmacare Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was R23,085 Mil. Therefore, Aspen Pharmacare Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 12.75%.
The historical rank and industry rank for Aspen Pharmacare Holdings's Return-on-Tangible-Equity or its related term are showing as below:
JSE:APN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -10.18 Med: 31.89 Max: 70.49
Current: -10.18
During the past 13 years, Aspen Pharmacare Holdings's highest Return-on-Tangible-Equity was 70.49%. The lowest was -10.18%. And the median was 31.89%.
JSE:APN's Return-on-Tangible-Equity is ranked worse than 81.22% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.925
vs JSE:APN: -10.18
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Aspen Pharmacare Holdings Return-on-Tangible-Equity Related Terms
Aspen Pharmacare Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Aspen Pharmacare Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:APN vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.75% mean?
Aspen Pharmacare Holdings (JSE:APN) has a Return-on-Tangible-Equity of 12.75% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aspen Pharmacare Holdings and its competitors. This is 60% below median its historical median of 31.89. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #731 out of 900 companies in the Drug Manufacturers industry, placing it in the top 81.2%.
Is Aspen Pharmacare Holdings' Return-on-Tangible-Equity too high?
Aspen Pharmacare Holdings' current Return-on-Tangible-Equity of 12.75% is 60% below median its 10-year median of 31.89. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. Aspen Pharmacare Holdings' value of 12.75% is 60.9% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #731 out of 900 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aspen Pharmacare Holdings has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #731 out of 900 companies for Return-on-Tangible-Equity. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.93. Aspen Pharmacare Holdings' value of 12.75% is 60.9% above this benchmark. While the company's 10-year median is 31.89 vs. the industry median of 7.93, Aspen Pharmacare Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current Return-on-Tangible-Equity of 12.75% is 60.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current Return-on-Tangible-Equity is 12.75%, which is 60% below median its own 10-year median of 31.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R170.84, compared to a current price of R150.32 — trading 12% below its estimated fair value. The current Return-on-Tangible-Equity is 12.75%, which is 60% below median its 10-year median of 31.89 and 60.9% above the Drug Manufacturers industry median of 7.93. Aspen Pharmacare Holdings' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current Return-on-Tangible-Equity is 12.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R150.32 is trading 12% below its estimated GF Value™ of R170.84.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
Return-on-Tangible-Equity: 12.75% (60% below median its 10-year median of 31.89)
GF Value™: R170.84 vs. price of R150.32 (12% below fair value)
Industry Position: 60.9% above the Drug Manufacturers median (#731 of 900)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
72GF Score
Get the complete analysis for JSE:APN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
